Allergic conjunctivitis is a disease characterised by inflammation of eyes due to an allergic reaction to substances such as pollen particles or mold spores. It is a collective term for eye infections such as seasonal allergic conjunctivitis (SAC), vernal keratoconjunctivitis (VKC), perennial allergic conjunctivitis (PAC), and atopic keratocongiuntivitis (AKC). Some of the most common forms of eye allergies are the SAC and PAC. According to a study published in the journal, Recent patents on inflammation and allergy drug discovery, these types of allergy are estimated to affect at least 15% to 20% of the global population. Allergic conjunctivitis could be acute (short-term) or chronic (lasts year-round) in nature. The most common symptom of the disease include swelling, itching, burning in eyes and light sensitivity. Allergic conjunctivitis is caused by allergens that trigger the release of histamine in the body. However, certain medications, contact lens solution or medicated eye drops may also cause Allergic conjunctivitis. Treatment involves a combination of prevention strategies and medications such as anti-inflammatory agents, antihistaminic agents and steroid eye drops.
The growth drivers for pipeline of allergic conjunctivitis include increasing market penetration of conjunctivitis medication due to mergers and acquisitions between major companies, rising demand for combination therapy due to superior efficacy, increasing exposure of to harmful pollutants and chemicals leading to an increase in prevalence of conjunctivitis globally and the rising awareness about the condition and the various treatment options available to treat the condition.
In May 2017, EyeCRO LLC and MPI Research Inc entered into a collaboration to develop new preclinical models of ophthalmic disease. The collaboration enables the two companies to develop and commercialize mammalian preclinical models for different ophthalmic diseases. The partnership aims to bring together the ophthalmology capabilities at MPI Research and the knowledge of new model development at EyeCRO. In May 2017, Ocular Therapeutix, Inc. started a study to confirm the effect of Dextenza on efficacy of the placebo insert used in previous studies in comparison to a rapidly resorbing placebo insert. Ocular Therapeutix, Inc. is now planning to initiate an additional Phase III clinical trial to assess Dextenza for the treatment of allergic conjunctivitis.
In February 2017, Bluejay Diagnostics, Inc. entered into a research collaboration with Hitachi Chemical Co., Ltd. to develop point of care test for allergic conjunctivitis. The technology would be helpful in the diagnosis of Allergic Conjunctivitis. Under the agreement, Hitachi Chemical agreed to deliver its technology, expertise to perform clinical trials and regulatory applications in the U.S., Europe and South America.
Some of the major companies having a pipeline for Allergic Conjunctivitis include Ocular Therapeutix, Inc., Vistakon Pharmaceuticals, Aciex Therapeutics, Inc., C.T. Development America, Inc., Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated, Laboratorios Sophia S.A de C.V., Eleven Biotherapeutics, Alcon Research, Ltd., Ophthalmic Research Associates, Inc., Aldeyra Therapeutics, Inc., Senju USA, Inc., Mati Therapeutics Inc., Noveome Biotherapeutics, Inc., Akorn, Inc., Aciex Therapeutics, Inc., Shire plc, Fovea Pharmaceuticals SA, Sun Pharma Advanced Research Company Limited, Allergan plc, Eye Therapies, LLC, ORA, Inc., Merck Sharp & Dohme Corp., Woodmont Pharmaceuticals, Inc.